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 Angina Patch:  Drug Delivery For Chest Pain 
 
Executive Summary 
Angina pectoris is defined as chest pain due to lack of blood and oxygen to the heart. 
Nitroglycerin is an organic nitrate which treats angina by vasodilating both arteries and 
veins to increase blood flow to the heart.  It is easy to develop nitroglycerin drug 
tolerance, and therefore drug application must occur at intervals of about 12 hours.   
While commercial products such as Deponit are suitable for treating mild cases of angina, 
a larger, daily dose of 40 mg of nitroglycerin is needed to treat the most acute cases.  The 
purpose of this study is to model the diffusion of nitroglycerin from a transdermal patch 
into the blood stream using the Deponit drug delivery system.  We determined that 
Deponit was indeed unable to deliver the necessary 40 mg of drug.  We therefore 
suggested a new patch which could treat acute angina, by modifying both patch geometry 
and the initial amount of drug in the reservoir. We also simulated drug delivery for a 36 
hour period of wearing the patch for 12 hours, not wearing the patch for 12 hours, and 
then reapplying a new patch for another 12 hours. We found that drug continued to be 
delivered even in absence of patch and after 36 hours, only ~125 mg of drug was 
delivered. The modified Thicker Patch with a 10x thicker drug reservoir than Deponit can 
physically hold 142 mg of drug and deliver 40 mg within 12 hours.  The modified patch 
is safe, non-toxic, cost effective, and capable of treating recalcitrant angina. To determine 
whether our assumptions were appropriate for our parameters, we performed two specific 
sensitivity analyses: varying the diffusivity of the skin and varying the diffusivity of the 
patch and the skin. From the sensitivity analysis we found that the amount of drug 
delivered to body is very sensitive to the diffusivity of the skin but insensitive to the 
diffusivity of the patch 
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Introduction 
 
Coronary heart disease is the number one cause of death in America and is most 
commonly caused by heart attacks and angina.  Angina pectoris is defined as chest pain 
due to lack of blood and oxygen to the heart muscle, which is generally caused by 
obstructions or spasms of the coronary arteries.  
 
The drug most commonly used to treat angina is nitroglycerin, also known as glycerol tri-
nitrate.  Nitroglycerin is for emergency, hospital usage and is usually only prescribed for 
a few days.  Nitrates dilate arteries by releasing nitric oxides which open up the smooth 
muscles in blood vessels. This vasodilation allows increased amounts of oxygen to flow 
to the heart to relieve chest pain.  A convenient method of administering nitroglycerin is 
via transdermal patches.    
 
“nitroglycerin is a dense, oily liquid that detonates if heated to 218°C” (Introduction to 
Mine Engineering) with a density of 1.6 g/cm at 25°C. When prescribed as heart 
medication, tiny amounts of nitroglycerin are diluted by inert matter, making it 
completely non-explosive.  A lethal dose of nitroglycerin ranges from 200-1000 mg.   
3 
Side effects of nitrates include flushing, headaches, and low blood pressure.       
 
Continuously worn patches have been shown to lead to drug tolerance within the first 24 
hours of therapy.  To prevent the development of drug tolerance, therapy incorporates 
nitrate-free periods.  Although a minimum nitrate-free interval has not been defined, data 
shows that 10-12 hours of being nitrate free is sufficient.  A typical treatment schedule 
includes a patch-on period of 12 -14 hours and a daily patch off period of 10 -12 hours. 
 
Deponit is a popular, commercial angina patch manufactured by the German company 
Schwarz Pharma.  Deponit is an acrylic, translucent, square patch with an area of 18 cm
2 
and a total thickness of 0.1 mm.  The patch can be applied to any part of the body free of 
hair and skin irregularities.  The patch consists of three layers (Figure 1).  The release 
liner protects the active surface of the drug containing matrix.  The backing film adjusts 
to different skin conditions including sweat.  The drug reservoir matrix holds 
nitroglycerin which is suspended in an acrylic co-polymer, such as polyethylene. 
 
Deponit delivers nitroglycerin at 15 µg/cm
2 per 
hour.  “Yet while products such as Deponit have 
received wide patient acceptance, the total daily 
nitroglycerin dose is not adequate to provide the 
substantial nitroglycerin doses required in the 
treatment of congestive heart failure or 
recalcitrant cases of angina pectoris” (US Patent 
Office).  To treat these conditions a patient needs 
to obtain daily doses of at least 40 mg.  
Figure 1:  Deponit patch schematic  
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Schematic 
 
The diagram below (Figure 2) indicates the thicknesses of each layer of patch, skin, and 
fat.  Here we assume that the properties are uniform throughout the skin and that the drug 
must diffuse through a layer of fat before being absorbed by the blood vessels.  The prior 
assumption was made due to the fact that diffusivity properties found in literature were 
uniform throughout the layers of skin.  The latter assumption was made based on 
information provided by Professor Gorewit at Cornell University.  Gorewit also provided 
the information that the diffusivity of nitroglycerin in fat is lower than that in skin, so it 
was therefore assumed to be ten times smaller. 
 
 
 
 
 
 
 
 
 
 
 
 
Refer to Appendix A for a thorough explanation of the various schematics used, the 
boundary conditions, initial conditions, simulation properties, and governing equation.   
 
 
The objective of this study is to analyze the diffusion of nitroglycerin from a transdermal 
patch into the blood using the Deponit drug delivery system.  Assuming an initial drug 
concentration in the drug reservoir, the amount of nitroglycerin delivered to the body will 
be measured after 12 hours using FIDAP.  The following are the main design objectives: 
Design Objectives 
Figure 2:  Diagram showing the dimensions of the three layers of the patch and skin 
 
1.  Confirm whether or not an effective amount of drug to treat congestive heart 
failure (40 mg cumulative) can be delivered to the body within 12 hours using the 
Deponit system. 
2.  Suggest a new patch, including a modified geometry and initial amount of drug in 
the reservoir, which can deliver 40 mg within this 12 hour window. 
3.  Model the diffusion of nitroglycerin over a 36 hour period, where the patch is 
applied for 12 hours, removed for the next 12 hours, and a new patch is applied 
again for 12 hours. 
4.  Determine whether toxic levels of nitroglycerin could be obtained during usage of 
the patch.   
5.  Evaluate the affect of patch position on the body to the amount of drug that can be 
delivered to the body will be studied.  Different areas on the body have varying 
thicknesses of fat, which may influence the diffusion of drugs to the body. 
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Results 
 
Preliminary Results for Original Schematic: 
The schematic described above with the patch, skin, and fat was modeled on Gambit and 
analyzed using FIDAP.  A 12 hours simulation was run, and the amount of drug that 
diffused from the patch and into the skin was calculated using the method in Appendix A.   
 
Some difficulty was encountered when attempting to find the drug delivery to the body 
using this model.  Initial results showed that no drug was able to completely diffuse to the 
blood vessels to be delivered to the body, as shown in the contour plot below: 
 
Layer 
of Fat 
 
 
 
 
 
 
 
 
 
 
Figure 3:  Contour of drug nitroglycerin Concentration after 12hr 
In this figure, the fat layer is entirely blue, while the skin layer has variations in color, 
showing that nitroglycerin traveled through the epidermis & dermis, but not the fat.  This 
was confirmed by the mean drug computation because at initial and final times the mean 
concentration of species was the same, indicating no diffusion of the drug into blood.  As 
seen below, a clear drop in the concentration of the nitroglycerin exists where fat begins. 
 
 
Layer of 
Fat Begins 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4:  Plot of nitroglycerin species along the axis at end time of 12 hours 
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Therefore, no drug got into the blood stream since the drug was never able to diffuse all 
the way through the fat. These results were not anticipated because it was assumed that 
the drug would diffuse through the entire fat layer before reaching the blood. 
 
These results led us to re-evaluate our model.  There are two logical reasons for the lack 
of diffusion of drug through the layer of fat:  the fat layer adds an extra 5.8mm for the 
drug to diffuse through, and the fact that the fat was assumed to have a lower diffusivity 
than that of skin.  Since nitroglycerin patches exist and are known to work, such as 
Deponit, the error in these preliminary results was determined to be due to incorrect 
assumptions in the model.  Upon further research of the physiology of skin, it was 
determined that there are many blood vessels prevalent in the dermis layer (which is 
above the fat layer) where the nitroglycerin can diffuse directly into the blood stream. 
 
Figure 5:  Cross section of skin showing location of blood vessels for drug diffusion 
 
Therefore, the new model assumed that nitroglycerin diffuses through the skin and 
directly into the blood without having to pass through the subcutaneous fat.  The new 
schematic for this model is similar to the previous one except that the fat layer has been 
removed, as seen above.  (Please refer to Appendix A for the modified mesh schematic) 
 
 
 
New Schematic With No Fat 
 
With the newly formulated model, the first objective was met by setting the dimensions 
and properties of the patch to that of the Deponit patch.  According to the information 
given by Schwartz Pharma, the patch delivers a flux of nitroglycerin of 15μg of drug per 
square centimeter of the patch.  Even if it was assumed that this flux remains constant, 
only 3.24mg of drug would be delivered to the body after a 12hr period.  Therefore, the 
only method to improve the performance of the Deponit patch system, without changing 
its geometry, would be to increase the initial concentration of nitroglycerin in the patch. 
 
Therefore, the initial amount of drug needed in the patch to deliver 40mg of nitroglycerin 
in a 12hr period must be determined.  However, FIDAP only allows us to simulate the 
forward solution: to find the drug delivery based on an initial concentration in the patch.  
Therefore, this is an inverse problem that can be solved by performing several iterations 
of the FIDAP simulation.  The drug delivered to the body could be simulated for various 
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values of drug concentration in the patch until the concentration that delivers 40mg was 
determined. 
 
The above procedure was used to determine the amount of drug needed in the Deponit 
patch for it to deliver 40mg of nitroglycerin to the body.  As seen below, it was found that 
the relationship between the amounts of drug delivered to the body was proportional to 
the amount of drug initially in the patch indicated by the linear graph (Figure 6).   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  Figure 6:  Amount of drug in Deponit vs. Amount of drug delivered to body 
 
Intuitively, as the initial amount of drug in the patch increases, the amount of drug 
delivery in a 12 hour period increases.  As shown in the graph above, the original Deponit 
design falls short of the required drug delivery.  The amount of drug required in the 
Deponit patch system would need to be as high as 850mg of nitroglycerin. 
 
There were two main problems associated with the above findings.  The first problem 
was an issue of economics and efficiency: 850mg of drug is needed to only deliver 40mg 
to the body.  This would cause the patch to become more expensive due to the unused 
nitroglycerin.  The second problem dealt with the physical properties of nitroglycerin.  As 
mentioned earlier, nitroglycerin is very explosive and remains stable in medical 
applications by diluting it in inert matter.  The current patch would have 850mg of 
nitroglycerin in a volume of 0.099cm
3.  This means the patch would have a concentration 
of nitroglycerin of 8.59g/cm
3.  Not only would this be dangerous, but this would also be 
physically impossible to have this much nitroglycerin in such a small volume of a patch 
since the density of pure nitroglycerin at 25
oC is only 1.6g/cm
3. 
 
Therefore, the Deponit drug delivery system remains inadequate for delivering enough 
nitroglycerin to the body to treat recalcitrant cases of angina.  The next step would be to 
redesign the geometry of the patch and perform the same analysis as above. 
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Patch with Larger Drug Reservoir 
In the Deponit simulation, the drug reservoir was very thin (only 0.055 mm thick) and 
there was very little drug getting to the bloodstream.  To allow a greater amount of drug 
to be placed into the drug reservoir, it was decided to increase the size of the patch’s drug 
matrix and see how that affected the diffusion.  The surface area of the patch was kept the 
same because it was believed that the limiting factor for this problem was the small 
thickness of the patch.  A new schematic was developed where the drug matrix was 
increased from 0.055 mm to 0.55 mm with all other values remaining constant.   
 
As before, the inverse problem was solved to find the initial amount of drug needed in the 
patch to deliver 40mg of drug in the body was determined.  As the following graph 
indicates, only 142mg of drug was needed in the patch: 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7:  Initial amount of drug in the matrix vs. how much is actually delivered to the body 
 
This result is better than that of the Deponit for two reasons: less nitroglycerin was 
needed overall, and the concentration of the nitroglycerin in the patch would be much 
lower because less drug was required in a larger patch.  Due to the fact that less 
nitroglycerin was needed to deliver 40mg means there would be less wasted drug in the 
patch.  Furthermore, this amount of drug in the patch was low enough to both physically 
fit in the patch and also remain dilute enough to be inert.  This patch would have 142mg 
of nitroglycerin in a volume of 0.99cm
3.  This means the patch would have a 
concentration of nitroglycerin of 0.143g/cm
3, compared to 1.6g/cm
3 for pure 
nitroglycerin. 
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36 Hour Patch Cycle 
 
Under normal conditions, the patch is applied for 12 hours, removed for 12 hours, and 
then a new patch is applied for another 12 hours.  However, in the time that the patch is 
removed, drug still remains in the skin and can continue to diffuse into the blood.  Even 
when the new patch is applied after 24 hours, there is still residual drug left in the skin 
from the first patch which can increase the dosage.  We would like to see how the amount 
of drug delivered to the blood changes in this 36 hours cycle.  
 
To model the 36 hour cycle, we used three separate, linked simulations.  The first 
simulation was run for 12 hours with 142 mg in the drug reservoir and used the normal 
initial conditions, boundary conditions, and properties. The second simulation read the 
final amounts of drug in the skin from the first simulation.  To mimic the removal of the 
patch, the patch initially had 0 mg of drug and the diffusivity of the patch was reduced to 
virtually zero.  The third simulation read the amount of drug in the skin from the second 
simulation and was run for another 12 hours, but again the diffusivity of the patch was 
returned to its normal value and the patch had an initial drug amount of 142 mg to 
simulate the application of a new patch.  The following graph and table describe the 
results:  
 
 
 
Figure 8: Drug delivery vs. time for a patch initially with 142 mg of drug 
 
 
 
 
 
 
 
 
Drug Delivery After each 
12hr Segment 
Drug Delivery in 
12hr Period (mg) 
Total Drug 
Delivered (mg) 
12 hours with Patch  40.025  40.025 
12 hours without Patch  33.960  73.984 
12 hours with Patch Again  51.803  125.788 
Table 1: Drug Delivery after each 12hr period 
 
  8Angina Patch:  Drug Delivery For Chest Pain 
As shown in Table 1, within the first 12 hour period, 40.025 mg of drug was delivered, 
which is sufficient to treat severe angina.  But in the next 12 hours, even after the patch 
was removed, an additional 33.960 mg of residual drug in the skin from the first patch 
was delivered.   Then when the new patch was applied for another 12 hours, 51.803 mg 
of drug was delivered for the same reason. 
 
The information from the 36 hour patch application serves to help understand the 
delivery of the drug over several cycles of patch application.  As shown in Figure 8, drug 
was still delivered during the 12 hour our period without the patch.  Hence, the rate of 
drug delivery remains relatively constant over 36 hours as in the graph.  Furthermore, the 
total amount of drug delivered over 36 hours was approximately 125mg of nitroglycerin.  
With a toxic dose of 200mg, it seems that the application of the patch for periods longer 
than 36 hours may become dangerous.  However, the lethal dosage is stated for an 
immediate dosage of 200mg, rather than a dosage over 36 hours.  Therefore, this level of 
drug delivery remains safe. 
 
Sensitivity Analysis 
 
Sensitivity analysis was performed to examine how changes in the skin diffusivity and 
patch diffusivity affected the amount of drug delivered to the body.  The following graph 
(Figure 9) shows the dependency of drug delivered on the value of the diffusivity of the 
skin. 
Diffusivity of Skin vs. Amount of Drug Delivered to Body
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Figure 9: Sensitivity of Dskin using a constant Dpatch = 0.05 mg/mm
3
 
The green dot represents the skin diffusivity value that we found in literature (4x10
-5 
mm
2/s) used in our previous simulations. The amount of drug delivered to the body 
increased as the diffusivity of the skin increased until the diffusivity was about 0.0004 
mm
2/s, which is where the graph leveled off with 99.99% drug going into the body. 
Initially there was a linear slope (amount of drug delivered to skin was proportional to the 
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diffusivity) before it leveled off. This occurred because the diffusivity of the skin got 
large enough to allow most of the drug to diffuse into the skin in a 12hr period. 
 
Diffusivity of Patch vs. Amount of Drug Delivered to Body 
in 12 hours
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Figure 10: Sensitivity Analysis of varying Dpatch and Dskin  
 
The graph above (Figure 10) depicts the sensitivity analysis of the diffusivity of the patch 
at various values for the diffusivity of the skin.  The green dot in the figure also 
represents the skin diffusivity and patch diffusivity values that we found in literature that 
we used in our main simulations. The figure above shows that even large differences in 
the magnitude of the diffusivity of the patch did not change the amount of drug delivered 
into the body despite various diffusivities of the skin.  There was practically no variation 
in the amount of drug delivered despite increasing and decreasing patch diffusivities.  
Clearly, as the diffusivity of the skin increased, the amount of drug delivered to the body 
increased, with 100% drug delivery for Dskin = 4x10
-3 and 4x10
-1 within 12 hours.   
 
Thus, the amount of drug delivered to body is very sensitive to Dskin, but insensitive to 
Dpatch.  Since drug delivery is very sensitive to the diffusivity of the skin, it is important to 
validate the value of this parameter from experimentation and literature. Because drug 
delivery is relatively insensitive to diffusivity of the patch, any uncertainty error in this 
parameter does not greatly affect simulation results. 
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Conclusions and Design Recommendations 
The objectives of this study were to analyze the diffusion of nitroglycerin from a 
transdermal patch into the blood stream using the Deponit drug delivery system. We 
wanted to specifically confirm whether or not Deponit could deliver an effective amount 
of drug to treat acute angina, suggest a new patch if Deponit was inefficient including a 
modified geometry and initial amount of drug in the reservoir, and model the diffusion of 
nitroglycerin over a 36 hour period. 
 
It was determined that nitroglycerin is absorbed into the body without having to diffuse 
through the subcutaneous fat layer since there are already blood vessels in the dermis 
layer of the skin meaning that the drug would be delivered throughout the body without 
having to first diffuse all the way through the fat layer. Our first model with the fat layer 
did not work as no drug was delivered through the fat.  For our second model, we 
removed the fat layer and therefore, could not study the affect of patch position on the 
body with variations in fat thickness to the amount of drug delivery.     
 
We found that Deponit is ineffective at delivering the 40 mg of nitroglycerin within 12 
hours needed to treat recalcitrant angina, even with an increased initial amount of drug. 
The commercial Deponit patch contains 3.24 mg of drug and delivers less than 1 mg in 
12 hours. We found that the Deponit patch would need to contain 850 mg to deliver 40 
mg of drug. Economically this means that more money would be wasted by the company 
to put a large amount of drug into the patch that only delivers approximately 5% of drug 
in reservoir to the body. Also in terms of manufacturability, it is not possible to fit 850mg 
of nitroglycerin in such a small patch reservoir.  
 
Since Deponit was found to be ineffective at treating acute angina we needed to modify 
the patch. We found that the modified patch with a thicker drug reservoir only needs 142 
mg of drug to deliver 40 mg to the body in 12 hours. By our calculations, this larger drug 
reservoir can physically hold 142 mg. The 142 mg of drug is safe, non-toxic (non-
explosive amount), and more cost effective since less drug is wasted and needed in patch. 
Since there is less drug in the reservoir, it is less expensive to manufacture and therefore 
more economical.  
 
Over a 36 hour period of wearing, removing, and applying a new patch it was found that 
the nitroglycerin continued to be delivered even in absence of the patch due to residual 
drug diffusing through the skin. Even after 36 hours, only ~125 mg of drug is delivered 
which is much less than the lethal dose of 200mg or more. 
 
From our sensitivity analysis, we found that amount of drug delivered to body is very 
sensitive to the diffusivity of the skin but insensitive to the diffusivity of the patch. Thus 
when modeling it is important to obtain the correct diffusivity of the skin to ensure 
accuracy in the simulation and any uncertainty in the diffusivity of patch has little effect.   
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Design Recommendations 
 
Based on the results from this study, possible improvements to the nitroglycerin 
transdermal drug delivery system include increasing the thickness of the drug reservoir 
and increasing the initial amount of drug in the patch.  As previously shown, a larger 
initial amount of drug in the patch increases the total drug delivery in 12 hours.  A thicker 
patch allowed for less drug needed in the reservoir and lead to a lower concentration of 
drug in the patch. 
 
In spite of these findings, future work should study the dependence of drug delivery on 
the thickness on the patch.  This study would require several meshes of the patch, which 
could be done in this study due to time constraints.  Furthermore, in consideration of the 
patient, the comfort and convenience of the patch must also be considered when 
increasing its thickness. 
 
As seen in the sensitivity analysis, the drug delivery of nitroglycerin is highly dependent 
on the diffusivity of the skin.  We therefore strongly suggest validating the value of this 
parameter experimentally in future research.  
 
Although much research is yet to be done to improve treatment for recalcitrant cases of 
angina, we believe this study provides promising results for the modification of currently 
available transdermal patches. 
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Appendix A:  Mathematical Statement of the Problem 
Geometry:  2-D axi-symmetric problem 
 
This geometry was chosen because the square shape of a transdermal patch could be 
approximated as a circular disc over a larger disc of skin and fat.   
 
Original Schematic with Patch, Skin, and Fat 
 
 
SKIN 
Dermis and 
Epidermis 
PATCH 
Drug 
Reservoir 
23.9 mm 
 0.055 mm 
2.535 mm 
47.8 mm 
AXIS 
r 
z 
FAT
Woman’s 
Bicep 
5.8 mm 
Patch top 
Flux = 0 
Patch  
Interface 
Skin Side 
Flux =0 
Fat Bottom 
CN =0 
Skin Axis 
Flux =0 
Patch Axis 
Flux =0 
Patch Side 
Flux =0 
AXIS 
Fat Axis 
Flux =0 
Fat Interface 
Fat Side 
Flux =0 
Skin Top 
Flux =0  Initial Conditions: 
 
Deponit 
CN (t =0) in drug reservoir 
= 0.0327 mg/mm
3  
 
 
For Deponit, the actual concentration of drug within the patch was not given, so an 
estimation was made based upon the average flux that the patch is reported to provide: 
 
Concentration of nitroglycerin in Deponit drug reservoir:  
=  [ (Ave Flux) * (Surface Area of patch) * (Time) ] / Volume of Patch 
=  [ (15 µg/cm
2 per hour) * (18 cm
2) * (12 hour) ] / 99 mm
3
=  0.0327 mg/mm
3
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Modified Schematic without the fat layer: 
 
 
 
Skin Side 
 
 
Figure 1:  Schematic of Deponit patch and our modified patch 
 
 
The following assumptions were made: 
 
•  No nitroglycerin is consumed in the drug reservoir or skin  
•  Skin = epidermis + dermis 
•  Thickness of skin is characteristic of a women’s bicep 
•  All drug that passes through the skin is absorbed directly by the blood    
 
  
SKIN 
Dermis 
and 
Epidermis 
PATCH 
Drug 
Reservoir 
23.9 mm 
Deponit: 0.055 mm 
New Patch: 0.55 mm 
2.535 mm 
47.8 mm 
AXIS 
r 
z 
Patch top 
Flux = 0 
Interface 
Flux =0 
Skin Bottom 
CN =0 
Skin Axis 
Flux =0 
Patch Axis 
Flux =0 
Patch Side 
Flux =0 
Two different meshes were created for:  
 
1.  The original transdermal patch, Deponit  
 
2.  Our modified patch which can deliver 40 mg of drug within 12 hours 
AXIS 
SKIN 
Dermis and 
Epidermis 
PATCH 
Drug 
Reservoir 
Skin Top 
Flux =0 
Initial Conditions: 
 
Deponit 
CN (t =0) in drug reservoir 
 = 0.0327 mg/mm
3  
 
Modified Patch  
CN (t =0) in drug reservoir  
= 0.1434 mg/mm
3
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Governing Equation: 
 
A x R
x
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x
c
u
t
c
+
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∂
= +
∂
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Since we are modeling the diffusion of nitroglycerin as an axi-symmetric problem and 
there is no convection or species generation occurring, the diffusion equation in radial 
coordinates reduces to     
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r = radial distance 
z = distance in the z direction 
t = time 
DN = diffusivity of nitroglycerin in various mediums (skin, patch) 
CN = concentration of nitroglycerin 
 
 
To increase the accuracy of our results, the physical properties and dimensions of our 
model will be non-dimensionalized to compensate for the small diffusivity values.    
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Non-Dimensionalization: 
 
Parameter 
Non-
Dimensionalized 
Values for 
Deponit 
 
Values for 
Modified Patch 
r  R
r
 
R = 0.055  R = 0.55 
z  R
z
 
R = 0.055  R = 0.55 
t 
2 R
Dt
  R = 0.055 
D = 4 x 10
-5
R = 0.55 
D = 4 x 10
-5
d  D
d
 
D = 4 x 10
-5 D = 4 x 10
-5
 
We chose to not non-dimensionalize the concentration values as they do not affect the 
other non-dimensionazlied variables in the equation. 
 
Non-Dimensionalized Mesh (using the Modified Patch): 
Original Coordinates (z,r)  Non-Dimensionalized Coordinates (z,r) 
(0,0) (0,0) 
(0,23.9) (0,  43.45) 
(0.55,0) (1,0) 
(0.55, 23.9)  (1,43.45) 
(0.55, 47.8)  (1, 86.91) 
(3.085, 0)  (5.609, 0) 
(3.085, 47.8)  (5.609, 86.91) 
 
Non-dimensionalized coordinates were determined by dividing all the original 
coordinates by R= 0.055 for the Deponit patch and R= 0.55 for the Modified Patch as 
shown in the example above. 
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Input Parameters: 
For Diffusion 
Parameter  Dimensionalized Value 
(mm
2/sec) 
Non-Dimensionalized  
Value 
Source 
Dpatch 0.05  1250  Hung, et al.   
Dskin 4.00 X 10
-5 1 Mitchem,  L 
Dfat 4.00 X 10
-6 n/a   Estimation 
 
Dskin is the diffusivity of nitroglycerin in the skin (includes dermis and epidermis) because 
only a single diffusivity value of nitroglycerin in skin could be found.   
 
Dpatch is the diffusivity of nitroglycerin in the drug matrix which is composed of 30% 
vinyl acetate.   
 
Dfat was only used with the original schematic which was later modified.                 
 
For Time
Parameter  Dimensionalized 
Value  
Non-Dimensionalized  
Value 
Source 
Tintial 0 0  N/A 
Tfinal 12 hours = 43200 s  5.71  N/A 
Tstep 432 s  0.0571  N/A 
 
Max number of time steps = 100 or 1000 
 
For Concentration 
Concentration was not non-dimensionalized.  Concentration of drug was only found 
within the drug reservoir of the patch.   
 
Parameter  Dimensionalized Value 
(mg/mm
3) 
Source 
Deponit : CN 0.0327  Online Deponit website 
New Patch : CN 0.1414 FIDAP  simulations 
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Computing Drug Diffusion into the Skin: 
The mean computation on FIDAP was used to calculate the mean concentration of drug 
left in the volume of the patch, skin (and fat depending on the mesh being used). This 
concentration could then be used to find the total amount of drug left in the system by 
multiplying by the volume.  Since the initial amount of drug in the patch is known from 
the initial condition in the patch, the drug delivered to the body could be found by the 
difference between the initial amount of drug and the drug remaining in the system after 
12 hours. 
 
For Deponit: 
Volume of patch     =   mm
cm
mm
cm 055 . 0 *
1
100
* 18 2
2
2
⎟ ⎟
⎠
⎞
⎜ ⎜
⎝
⎛
 
                            =  99 mm
3 
Volume of skin                       =  2.535 mm * Π * (47.8 mm)
2 
                                                                        =  18196.32 mm
3 
Total Volume                           = 990 mm
3 + 181196. 32 mm
3 
                                                                         = 18295.32 mm
3 
 
For Modified patch: 
Volume of patch     =   mm
cm
mm
cm 55 . 0 *
1
100
* 18
2
2
2
⎟ ⎟
⎠
⎞
⎜ ⎜
⎝
⎛
 
                            =  990 mm
3 
Volume of skin                       =  2.535 mm * Π * (47.8 mm)
2 
                                                                        =  18196.32 mm
3 
Total Volume                           = 990 mm
3 + 181196. 32 mm
3 
                                                                         = 19186.322 mm
3 
 
Amount of Drug Diffused into Skin:  
= (Initial concentration in patch * Volume of patch) -  (Mean concentration of drug     
calculated from FIDAP * Total Volume)  
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36 hour cycle of wearing the patch on and off (for Modified Patch): 
 
To simulate wearing the patch for 12 hours, removing the patch for 12 hours, and adding 
a new patch for 12 hours we: 
•  Ran three separate simulations for each of the three periods 
•  Varied the initial conditions and patch diffusivity properties for each simulation 
•  Read the results from the previous simulation for the next simulation 
 
Simulation  Real Time 
(hr) 
Entity Initial 
Condition 
(mg/mm
3) 
Dimensionalized 
Properties 
(mm
2/s) 
Patch on   0-12  Patch    
Skin 
CN= 0.1434  
CN = 0 
Dpatch = 0.05 
Dskin = 4 x 10
-5  
Patch off  12-24  Patch    
Skin 
CN= 0  
CN = 0 
Dpatch ~ 1 x 10
-11 
Dskin = 4 x 10
-5  
Patch on  24-36  Patch    
Skin 
CN= 0.1434  
CN = 0 
Dpatch = 0.05 
Dskin = 4 x 10
-5  
 
To simulate the removal of the patch, the CN
 in the patch was set to 0 and the Dpatch was 
set to 0.  However within FIDAP, Dpatch cannot be defined as 0, so for the patch off 
period, 0 was approximated as 1 x 10
-11.   
  Figure 11:  Patch on for 12 hours (file: tps1)                            Figure 12:  Patch off for 12 hours (file: tps2) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
                                                Figure 13:  New patch on for next 12 hours (file: tps3) 
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Appendix B:   
 
Problem Statement: 
 
PROB (AXI-, ISOT, NOMO, TRAN, LINE, FIXE, NEWT, INCO, SPEC = 1.0) 
 
 
Descriptor  Symbol  Explanation 
Geometry Type  AXI  Axi-symmetric:  Patch is assumed to be circular 
and the axis runs through the center of the patch  
Temperature 
Dependence 
ISOT  Isothermal:  No heat equation used 
Flow Type  NOMO  No momentum:  There is no fluid flow 
Simulation Type  TRAN  Transient:  Interested in amount of drug delivered 
versus time 
Convective Term  LINE  No convection occurring 
Surface Type  FIXE  Geometry is fixed 
Fluid Type  NEWT  If fluid was present, it would be Newtonian 
Flow Regime  INCO  Drug is incompressible 
Species Dependence  SPEC = 1.0  nitroglycerin is the only species being analyzed 
 
 
Solution Statement: 
 
SOLU (S.S. = 50, VELC = 0.100000000000E-02, RESC = 0.100000000000E-01, 
       SCHA = 0.000000000000E+00, ACCF = 0.000000000000E+00) 
 
Descriptor  Symbol  Value  Explanation 
Solution Method  SS   50  Successive 
Substitution = 50 
iterations per time 
step  
Velocity 
Convergence 
VELC   1 x10
-3 Velocity convergence 
tolerance 
Residual 
Convergence 
RESC 1  x10
-2 Residual vector 
convergence 
tolerance 
Solution Change  SCHA  0  Default percentage 
change in solution 
magnitude 
Relaxation Factor  ACCF  0  Acceleration of 
solver set to zero 
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Time Integration Statement: 
 
TIME (BACK, FIXE, TSTA = 0.000000000000E+00, TEND = 5.71, 
       DT = 0.571000000000E-01, NSTE = 100) 
 
Descriptor  Symbol  Value  Explanation 
Time Integration  BACK  n/a  Backward integration 
using (t + ∆t) 
Time Step Algorithm 
 
FIXE  n/a  Fixed time step 
Start Time 
 
TSTA   0  Beginning time is 0 sec 
End Time 
 
TEND   5.71  Ending time is 12 hours 
Time Step 
 
DT   0.0571  Time increment is 432 s 
Number of Time 
Steps 
NSTE  100  There are 100 fixed time 
steps 
 
Note:  Values of the start and end time are non-dimensionalized. 
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Plot of the element mesh 
 
 
Figure 14:  Plot of the elemental, non-uniform mesh 
 
This mesh consists of two different layers: nitroglycerin drug matrix and the skin.  The 
top layer is the very thin nitroglycerin reservoir.  The skin layer consists of both the 
dermis and epidermis.  The mesh is composed of structured quad elements.  The mesh is 
non-uniform with more elements in the patch and at the patch/skin interface to account 
for the larger initial changes in drug concentration, while the mesh in the remainder of the 
skin is comprised solely of identically sized elements.  
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Convergence of Mesh 
 
Amount of Drug Delivered to the Body vs. Number of Nodes
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Figure 15:  Mesh convergence 
 
A mesh convergence test was performed to see the affect of changing the number of 
nodes on the amount of drug delivered to the body.  As shown above, after about 500 
nodes, the amount of drug delivered to the body did not change significantly with the 
number of mesh nodes.  We chose to use 501 nodes to decrease the computation time 
while still maintaining a high level of accuracy. 
 
Convergence of Time Step 
Amount of Drug Delivered to the Body vs. Time Step
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Figure 16:  Amt of Drug Delivered to the Body vs. Time Step within 12 hrs using modified patch  
 
As shown above, increasing the time step does create affect the final solution at all.  
Therefore, the time step of 100 was chosen to minimize the computation time, but still 
maintain a high level of accuracy.   
  23Angina Patch:  Drug Delivery For Chest Pain 
 
FDREAD files 
 
For patch on 12 hours 
Files:  tsp1 
 
/  INPUT FILE CREATED ON 12 Apr 06 AT  17:12:35 
/ 
/ 
/ ***  FICONV Conversion Commands ***  
/ ***  Remove / to uncomment as needed 
/ 
/  FICONV(NEUTRAL,NORESULTS,INPUT) 
/  INPUT(FILE= "tps1.FDNEUT") 
/  END 
/  *** of FICONV Conversion Commands 
/ 
TITLE 
 
/ 
/ ***  FIPREP  Commands *** 
/ 
FIPREP 
 PROB (AXI-, ISOT, NOMO, TRAN, LINE, FIXE, NEWT, INCO, SPEC = 1.0) 
 PRES (MIXE = 0.100000000000E-08, DISC) 
 EXEC (NEWJ) 
 SOLU (S.S. = 50, VELC = 0.100000000000E-02, RESC = 0.100000000000E-01, 
       SCHA = 0.000000000000E+00, ACCF = 0.000000000000E+00) 
 TIME (BACK, FIXE, TSTA = 0.000000000000E+00, TEND = 5.71, 
       DT = 0.571000000000E-01, NSTE = 100) 
 OPTI (SIDE) 
 DATA (CONT) 
 PRIN (NONE) 
 POST (RESU) 
 SCAL (VALU = 1.0) 
 ENTI (NAME = "patch", SOLI, PROP = "mat1", SPEC = 1.0, MDIF = "C1_patch") 
 ENTI (NAME = "skin", SOLI, PROP = "mat2", SPEC = 1.0, MDIF = "C1_skin") 
 ENTI (NAME = "patchtop", PLOT) 
 ENTI (NAME = "patchside", PLOT) 
 ENTI (NAME = "patchaxis", PLOT) 
 ENTI (NAME = "interface", PLOT) 
 ENTI (NAME = "skintop", PLOT) 
 ENTI (NAME = "skinside", PLOT) 
 ENTI (NAME = "skinbottom", PLOT) 
 ENTI (NAME = "skinaxis", PLOT) 
 DIFF (SET = "C1_patch", CONS = 1250.0) 
 DIFF (SET = "C1_skin", CONS = 1.0) 
 BCNO (SPEC = 1.0, CONS = 0.000000000000E+00, ENTI = "skinbottom") 
 BCFL (SPEC = 1.0, CONS = 0.000000000000E+00, ENTI = "patchtop") 
 BCFL (SPEC = 1.0, CONS = 0.000000000000E+00, ENTI = "patchside") 
 BCFL (SPEC = 1.0, CONS = 0.000000000000E+00, ENTI = "patchaxis") 
 BCFL (SPEC = 1.0, CONS = 0.000000000000E+00, ENTI = "skinside") 
 BCFL (SPEC = 1.0, CONS = 0.000000000000E+00, ENTI = "skinaxis") 
 ICNO (SPEC = 1.0, CONS = 0.327000000000E-02, ENTI = "patch") 
 ICNO (SPEC = 1.0, CONS = 0.000000000000E+00, ENTI = "skin") 
 EXTR (ON, AFTE = 5, EVER = 5, ORDE = 3, NOKE, NOFR) 
END 
/  *** of FIPREP Commands 
CREATE(FIPREP,DELE) 
CREATE(FISOLV) 
PARAMETER(LIST) 
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